SuFEx-based antitubercular compound irreversibly inhibits Pks13 - Nature A preclinical covalent compound, CMX410, contains a aryl fluorosulfate warhead that targets the acyltransferase domain of Mtb Pks13, an essential enzyme in cell-wall biosynthesis, making it a pro...

🧬 New Nature study: CMX410 shows promise as a novel TB drug targeting #Pks13, effective even against drug-resistant strains. This could help shorten long TB treatments.

🔗 www.nature.com/articles/s41...

#Tuberculosis #GlobalHealth #DrugDiscovery